Withdrawal of dornase alfa increases ventilation inhomogeneity in children with cystic fibrosis
- 19 February 2021
- journal article
- research article
- Published by Elsevier BV in Journal of Cystic Fibrosis
- Vol. 20 (6), 949-956
- https://doi.org/10.1016/j.jcf.2021.02.004
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosisEuropean Respiratory Journal, 2010
- Hypertonic saline improves the LCI in paediatric patients with CF with normal lung functionThorax, 2010
- Cystic fibrosis lung disease starts in the small airways: Can we treat it more effectively?Pediatric Pulmonology, 2010
- Inert Gas Washout: Theoretical Background and Clinical Utility in Respiratory DiseaseRespiration, 2009
- Standardisation of spirometryEuropean Respiratory Journal, 2005
- A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalitiesThe Journal of Pediatrics, 2001
- Body mass index of 0 to 45-y-old Danes: reference values and comparison with published European reference valuesInternational Journal of Obesity, 2001
- In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis.Thorax, 1996
- Effect of Aerosolized Recombinant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients with Cystic FibrosisThe New England Journal of Medicine, 1994
- Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosisThe Lancet, 1993